Abstract
Use of antiretrovirals is associated to body fat accumulation. We measured body composition in adolescents living with HIV switched to a dolutegravir-containing regimen. Trunk fat and trunk/body fat ratio markedly increased after 12 months. Total and low density lipoprotein cholesterol decreased after 3 months. Increase in trunk fat may put at risk of future cardiovascular problems, despite improvement in the lipid profile.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Publication types
-
Observational Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Abdominal Fat / drug effects
-
Adolescent
-
Anti-Retroviral Agents / metabolism
-
Anti-Retroviral Agents / therapeutic use*
-
Body Fat Distribution*
-
Cohort Studies
-
HIV Infections / drug therapy*
-
HIV Infections / metabolism
-
HIV Integrase Inhibitors / metabolism
-
HIV Integrase Inhibitors / therapeutic use*
-
Heterocyclic Compounds, 3-Ring / metabolism
-
Heterocyclic Compounds, 3-Ring / therapeutic use*
-
Humans
-
Lipid Metabolism / drug effects*
-
Lipoproteins / metabolism
-
Lipoproteins, LDL / metabolism
-
Longitudinal Studies
-
Oxazines / metabolism
-
Oxazines / therapeutic use*
-
Piperazines / metabolism
-
Piperazines / therapeutic use*
-
Pyridones / metabolism
-
Pyridones / therapeutic use*
-
Young Adult
Substances
-
Anti-Retroviral Agents
-
HIV Integrase Inhibitors
-
Heterocyclic Compounds, 3-Ring
-
Lipoproteins
-
Lipoproteins, LDL
-
Oxazines
-
Piperazines
-
Pyridones
-
dolutegravir